Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (288)	1/7/1999 9:11:00 PM
From: Epicenter	Respond to of 656

Peter: A belated response regarding Celgene. I am not too positive on thalidomide and its derivatives. Molecular target is not know and thus mechanism of action not known. It will also always have association witht the 1950's disaster with thalidomide. TNF pathway is a very comlicated pathway so the critical test will come in how one accomplishes specificity. This may turn out to be easier with protein drugs than by small molecule although I know of at least a dozen companies working on the TNF pathway small molecule inhibitor. To my knowledge, none has been identified that is anywhere near commercialization. Epicenter